Development

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Articles

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery. 

Considerations for DPIs and MDIs in Inhalation Drug Delivery

When designing and manufacturing a pMDI or DPI combination drug-delivery device, the commercial stage should be kept in mind from the beginning of development.  

Best Practices in Manufacturing Inhalation Drugs

Editor of Pharmaceutical Technology Europe

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

Getting a Nose for Vaccines

FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension. 

FDA Grants Orphan Drug Designation to Aerami Therapeutics’s Imatinib

Sara Sefton is technical manager, pharmaceutical development, Vectura.

Fergus Manford is patent attorney, intellectual property, Vectura.

Tim Gardner is director, manufacturing and NPI, Vectura.

Andrew Walker is vice president, device development, Vectura.

The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product. 

Integrated Approach Facilitates Inhalation Drug Development

Susana Saldanha, PharmD, is formulation development scientist at Hovione.

Beatriz Fernandes, MSc, is a formulation development scientist at Hovione

João Ventura, PhD, is director of Technology Development and Licensing at Hovione Technology.

Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.

Spray Drying as an Enabling Technology for Inhalation Drug Delivery

Particle engineering is a vital tool in overcoming many formulation challenges, and technological advances are enabling developers to achieve the full potential of pipeline molecules.

Moving Beyond Particle Size Control

Vectura will support the product from Phase I through to commercial launch. 



Vectura and Monash University to Develop Inhaled Oxytocin for the Prevention of Postpartum Hemorrhage

Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.

Key Considerations When Repositioning a Known Drug for Inhalation Therapy

The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

Formulation and Drug Delivery, Inhalation Drugs